Mogens Helweg Claesson

Mogens Helweg Claesson

No job title VIP


Publication year:
All
211 - 220 out of 221Page size: 10
Sort by: Title
  1. Published

    Tumour necrosis factor-alpha (TNF-alpha) transcription and translation in the CD4+ T cell-transplanted scid mouse model of colitis

    Williams, A. M., Whiting, C. V., Bonhagen, K., Reimann, J., Bregenholt, S., Claesson, Mogens Helweg & Bland, P. W., 1 Jun 1999, In: Clinical and Experimental Immunology. 116, 3, p. 415-24 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck

    Hald, J., Rasmussen, N. & Claesson, Mogens Helweg, 1 Oct 1995, In: Cancer Immunology, Immunotherapy. 41, 4, p. 243-50 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study

    Burgdorf, S. K., Fischer, A., Claesson, Mogens Helweg, Kirkin, A. F., Dzhandzhugazyan, K. N. & Rosenberg, Jacob, 2006, In: Journal of Experimental & Clinical Cancer Research. 25, 2, p. 201-6 5 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers.

    Svane, I. M., Pedersen, Anders Elm, Johansen, J. S., Johnsen, H. E., Nielsen, D., Kamby, C., Ottesen, S., Balslev, E., Gaarsdal, E., Nikolajsen, K. & Claesson, Mogens Helweg, 2007, In: Cancer Immunology, Immunotherapy. 56, 9, p. 1485-99 14 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study.

    Svane, I. M., Pedersen, Anders Elm, Johnsen, H. E., Nielsen, D., Kamby, C., Gaarsdal, E., Nikolajsen, K., Buus, Søren & Claesson, Mogens Helweg, 2004, In: Cancer Immunology, Immunotherapy. 53, 7, p. 633-41 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Veto Suppression: The Peripheral Way of T Cell Tolerization

    Tscherning, T. & Claesson, Mogens Helweg, 1993, In: Experimental and Clinical Immunogenetics. Vol 10, p. 179-188

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Veto cell suppression mechanisms in the prevention of allograft rejection

    Jacobsen, I. M. & Claesson, Mogens Helweg, 1 Mar 1998, In: Acta Pathologica Microbiologica et Immunologica Scandinavica. 106, 3, p. 345-53 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Veto-like down-regulation of T helper cell reactivity in vivo by injection of semi-allogeneic spleen cels

    Tscherning, T. & Claesson, Mogens Helweg, 1991, In: Immunology Letters. 29, p. 223-28

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Why current peptide-based cancer vaccines fail – lessons from the three Es

    Claesson, Mogens Helweg, 2009, In: Immunotherapy. 1, 4, p. 513-516 4 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Why current peptide-based cancer vaccines fail: lessons from the three Es

    Claesson, Mogens Helweg, Jul 2009, In: Immunotherapy. 1, 4, p. 513-6 4 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1...18 19 20 21 22 23 Next

ID: 5261